These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20061646)

  • 21. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
    Ye BS; Lee WW; Ham JH; Lee JJ; Lee PH; Sohn YH;
    Eur J Neurol; 2016 May; 23(5):948-57. PubMed ID: 26917248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [From mild cognitive impairment to dementia: what is the role of public health?].
    Vanacore N; Di Pucchio A; Lacorte E; Bacigalupo I; Mayer F; Grande G; Cesari M; Canevelli M
    Recenti Prog Med; 2017 May; 108(5):211-215. PubMed ID: 28643811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.
    Leaver K; Poston KL
    Neuropsychol Rev; 2015 Dec; 25(4):411-23. PubMed ID: 26626621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
    de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
    J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia.
    Stefani A; Sancesario G; Pierantozzi M; Leone G; Galati S; Hainsworth AH; Diomedi M
    J Neurol Sci; 2009 Aug; 283(1-2):109-15. PubMed ID: 19278690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
    Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
    Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers in dementia: clinical utility and new directions.
    Ahmed RM; Paterson RW; Warren JD; Zetterberg H; O'Brien JT; Fox NC; Halliday GM; Schott JM
    J Neurol Neurosurg Psychiatry; 2014 Dec; 85(12):1426-34. PubMed ID: 25261571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
    Li G; Sokal I; Quinn JF; Leverenz JB; Brodey M; Schellenberg GD; Kaye JA; Raskind MA; Zhang J; Peskind ER; Montine TJ
    Neurology; 2007 Aug; 69(7):631-9. PubMed ID: 17698783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
    Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
    J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment.
    Forlenza OV; Diniz BS; Talib LL; Radanovic M; Yassuda MS; Ojopi EB; Gattaz WF
    Braz J Psychiatry; 2010 Sep; 32(3):216-22. PubMed ID: 20414590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
    Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
    J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.
    Herukka SK; Hallikainen M; Soininen H; Pirttilä T
    Neurology; 2005 Apr; 64(7):1294-7. PubMed ID: 15824371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Who needs cerebrospinal biomarkers? A national survey in clinical practice.
    Troussière AC; Wallon D; Mouton-Liger F; Yatimi R; Robert P; Hugon J; Hannequin D; Pasquier F; Paquet C
    J Alzheimers Dis; 2014; 40(4):857-61. PubMed ID: 24577469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study.
    Tondelli M; Bedin R; Chiari A; Molinari MA; Bonifacio G; Lelli N; Trenti T; Nichelli P
    Clin Chem Lab Med; 2015 Feb; 53(3):453-60. PubMed ID: 25274948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline.
    Nettiksimmons J; Harvey D; Brewer J; Carmichael O; DeCarli C; Jack CR; Petersen R; Shaw LM; Trojanowski JQ; Weiner MW; Beckett L;
    Neurobiol Aging; 2010 Aug; 31(8):1419-28. PubMed ID: 20542598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
    Cavedo E; Lista S; Khachaturian Z; Aisen P; Amouyel P; Herholz K; Jack CR; Sperling R; Cummings J; Blennow K; O'Bryant S; Frisoni GB; Khachaturian A; Kivipelto M; Klunk W; Broich K; Andrieu S; de Schotten MT; Mangin JF; Lammertsma AA; Johnson K; Teipel S; Drzezga A; Bokde A; Colliot O; Bakardjian H; Zetterberg H; Dubois B; Vellas B; Schneider LS; Hampel H
    J Prev Alzheimers Dis; 2014 Dec; 1(3):181-202. PubMed ID: 26478889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.